Forward Looking Statement

This presentation may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. In particular, this presentation may include forward looking information relating to the Phase 3 BETonMACE2 clinical trial, Covid-19, vascular cognitive dementia, chronic kidney disease, Fabry disease and pulmonary arterial hypertension clinical trials, and the potential role of apabetalone in the treatment of high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact
Donald McCaffrey
Email: don@resverlogix.com
Phone: 587-390-8887
Website: www.resverlogix.com
Key Highlights

Apabetalone is a first-in-class Phase 3 asset with a demonstrated cardio-protective benefit in high-risk cardiovascular, diabetic, and chronic kidney disease patients – utilizing advanced epigenetics to regulate expression of multiple disease-causing genes.

FDA Breakthrough Therapy Designation awarded to Apabetalone for prevention of Major Adverse Cardiovascular Events (MACE) in high-risk CVD patients, demonstrating a critical ability to obtain expedited regulatory approval for a lead indication.

FDA endorsement was based on a Phase 3 study in which Apabetalone demonstrated up to a 63% hazard reduction, with a P-value of p=0.0002, in MACE and hospitalization for Congestive Heart Failure (CHF) in high-risk CVD patients.

Numerous publications, including Cell and Nature, have demonstrated the potential of Apabetalone’s dual anti-viral and anti-inflammatory approach in preventing and treating the severe and lasting effects of COVID-19.

Resverlogix and EVERSANA™, a world leader in next generation commercialization, have partnered to accelerate the commercialization of Apabetalone for COVID-19 by 2-3 years.

With approvals from Health Canada and Brazil, Resverlogix commenced clinical trials of apabetalone in COVID-19. The FDA has granted a Type C meeting to advance to Phase 3. Trial protocol approval is expected to follow the scheduled meeting (Early August).
Resverlogix: Key Milestones

**September**
- PAH trial successfully completed with Laval – Quebec Heart & Lung Institute
- Cognitive Effects of Apabetalone Publication by Dr Jeff Cummings (Journal of Alzheimer’s Disease)

**October**
- 1st Ethics Committee approval for use of apabetalone in human COVID patients

**November**
- The Kingdom of Morocco’s Ministry of Health support COVID-19 trial

**February**
- PAH Publication (American Journal of Respiratory & Clinical Care Medicine)

**April**
- EVERSANA™ extends the scope of their work to include PAH and BETonMACE2
- Hepalink extends $6MM debenture a full year

**May**
- FDA Type C Meeting announced for Phase 3 COVID trial (CORAL). Phase 2 no longer required
- Fabry disease publication (Pharmacology Research & Perspectives)

**June**
- MoA publication on Pan vs Selective BETi (Biomedicine & Pharmacotherapy)
Clinical Programs: Recent Advancements

We are a global leader in the development of epigenetic therapies for the treatment of chronic disease.
Four Pillars: Therapeutic Product Development

1. Intellectual Property & Academic Support
   - Multiple patents
   - Coverage to 2040
   - Over 40 publications

2. Regulatory Approval Pathway
   - Breakthrough Therapy Designation
   - Additional indications under review - Type C meeting

3. Commercialization Strategy & Capacity
   - Expanded partnership with EVERSANA™
   - Detailed COVID-19 commercialization work in place

4. Financing
   - Industry-wide downturn nearing 80%
   - Alternate non-equity options being pursued
Biotechnology Market: Severe Industry-wide Downturn

Biotech Performance by Market Cap since XBI High (Feb 2021)

Source: Rapport Biotech, Analysis by Peter Kolchinsky, Phd, May 2022
Clinical Trial Timelines: 
**Accelerated Development with Interim Analyses**

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>H2</td>
<td>H1</td>
<td>H2</td>
</tr>
<tr>
<td><strong>BETonMACE2</strong></td>
<td>Planning &amp; Documents Finalization</td>
<td>Start-up</td>
<td>Screening &amp; Recruitment</td>
</tr>
<tr>
<td></td>
<td>Start-up</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recruitment</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>First Patient In</td>
<td></td>
</tr>
<tr>
<td><strong>CORAL</strong></td>
<td>Planning &amp; Documents Finalization</td>
<td>Start-up</td>
<td>Screening &amp; Recruitment</td>
</tr>
<tr>
<td></td>
<td>Start-up</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recruitment</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>First Patient In</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Analysis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Projected timelines to interim analysis only, subject to change.
BETonMACE2: Registration Enabling Design

BETonMACE2 will be larger and have a greater concentration of patients in the subgroups where apabetalone has the most benefit.

<table>
<thead>
<tr>
<th></th>
<th>BETonMACE</th>
<th>BETonMACE2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample Size</td>
<td>2418</td>
<td>3600</td>
</tr>
<tr>
<td>Low eGFR</td>
<td>12%</td>
<td>25%</td>
</tr>
<tr>
<td>SGLT2i or DPP4i</td>
<td>22%</td>
<td>100%</td>
</tr>
</tbody>
</table>

Approximate Cost: $80MM
Resverlogix Cost: $40MM +

BETonMACE2 is in the planning stage and trial design is subject to regulatory approval.
BETonMACE2: Treating Patients Who Stand to Benefit the Most

BETonMACE Study population

eGFR < 60 mL/min/1.73m²  p = 0.03

SGLT2i or DPP4i Co-administration  p = 0.0002

MACE Hazard Ratio
(95% Confidence Interval)
COVID-19 Program Update and Progress
The Pandemic Continues to Unfold

Apabetalone can play an important role in preventing negative outcomes in COVID-19

Source: WHO, COVID-19 case counts by region (June 2022)
COVID-19 Program: Scientific Advisory Board

• A team of highly engaged, experienced, and respected COVID-19 clinical trial investigators

• Infectious Disease, Critical and Emergency Care Specialists

JUDITH S. CURRIER, MD
Professor of Medicine
Division Chief, Infectious Diseases
Director, UCLA Clinical AIDS Research and Education
UCLA Health
Los Angeles, California

PRINCY N. KUMAR, MD, FIDSA, MACP
Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Tropical Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, District of Columbia

CARLOS DEL RIO, MD
Executive Associate Dean
Distinguished Professor
Emory School of Medicine
Atlanta, Georgia

Tiffany M. Osborn, MD,
MPH, FCCM, FACEP, FAEM
Professor of Surgery
and Emergency Medicine
Barnes-Jewish Hospital
St. Louis, Missouri

FRANCO R. D’ALESSIO, MD
Associate Professor Of Medicine
Johns Hopkins University
Attending Physician
Johns Hopkins Hospital
Baltimore, Maryland

BARRY ZINGMAN, MD
Professor
Albert Einstein College of Medicine
Bronx, New York
Apabetalone in COVID-19: A Unique Dual-mechanism

1. **Anti-viral**
   Apabetalone blocks cellular entry of SARS-CoV-2 by reducing expression of the key receptor ACE2.

2. **Anti-inflammatory**
   Apabetalone prevents runaway inflammatory responses to the virus, which drive severe outcomes.

---

**Article**

*Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro*

Dean Gilham 1,2, Audrey L. Smith 3, Li Fu 3, Dalia Y. Moore 3,4, Abenaya Muralidharan 1,2, St. Patrick M. Bird 1, Stephanie C. Stote 1, Jan O. Johannsson 5, Michael Sweeney 1, Norman C. W. Wong 1, Ewelina Kulikowski 1,4 and Dalia El-Gamal 2,3,4*

**Cell**

*BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection*

Richard J. Mills 1, Sean J. Humphrey 1, Patrick R.J. Fortune 1, Mary Lor 1, Simon R. Foster 1, Gregory A. Quasie-Ryan 3, Rebecca L. Johnston 1, Troy Dunmen 1, Cameron Bishop 1, Rajeev Reddy 1, Neda R. Mehdiabadi 2, Christopher Halliday 2, Dean Gilham 1, ..., James E. Hudson 1,4,5,6
COVID-19: Apabetalone and Disease Progression

<table>
<thead>
<tr>
<th>Time</th>
<th>Phase</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 Days</td>
<td>Point of Infection</td>
<td>Viral Growth and Activity</td>
</tr>
<tr>
<td>5 Days</td>
<td>Early Infection</td>
<td>Asymptomatic (~35%)</td>
</tr>
<tr>
<td>10 Days</td>
<td>Pulmonary Phase</td>
<td>Mild to Moderate Symptoms (~45%)</td>
</tr>
<tr>
<td>28 Days</td>
<td>Hyper-inflammatory Phase</td>
<td>Severe to Critical Symptoms (~20%)</td>
</tr>
<tr>
<td></td>
<td>Chronic COVID-19</td>
<td>Ongoing Symptoms (~10%)</td>
</tr>
</tbody>
</table>

Potential for Apabetalone Treatment

Source: CDC, Karolinska Institutet
We partnered with EVERSANA™ to support the development of apabetalone. Together, we can leverage our emerging technology platform to help patients worldwide who suffer from chronic disease.
Aligned Objectives:
EVERSANA™’s Dedicated Commercialization Team
Contact:

Donald McCaffrey, President & CEO
Email: don@resverlogix.com
Phone: 587-390-8887
Website: www.resverlogix.com